Castleview Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Castleview Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$254K	Buy	+1,602	New	+$217K	0.11%	184
2025 Q1	–	Sell	-270	Closed	-$24.7K	–	581
2024 Q4	$24.7K	Sell	270 -3,449	-93%	-$334K	0.01%	439
2024 Q3	$367K	Buy	3,719 +231	+7%	+$22.7K	0.21%	116
2024 Q2	$323K	Buy	3,488 +1,538	+79%	+$138K	0.18%	126
2024 Q1	$185K	Buy	1,950 +1,839	+1,657%	+$171K	0.1%	187
2023 Q4	$9.91K	Hold	111	–	–	0.01%	514
2023 Q3	$8.11K	Hold	111	–	–	0.01%	439
2023 Q2	$9.23K	Hold	111	–	–	0.01%	444
2023 Q1	$8.46K	Hold	111	–	–	0.01%	447
2022 Q4	$9.21K	Hold	111	–	–	0.01%	379
2022 Q3	$9K	Sell	111 -7,715	-99%	-$650K	0.01%	404
2022 Q2	$326K	Buy	7,826 +7,715	+6,950%	+$579K	0.26%	88
2022 Q1	$9K	Buy	+111	New	+$10.3K	0.01%	512
2021 Q2	$15K	Buy	+111	New	+$14.6K	0.01%	610

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Castleview Partners's XBI Position: Q2 2026 in Review

Castleview Partners opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 1,602 shares worth $254K. The stake represents 0.11% of the portfolio and ranks #184 among its holdings. This is a return to the name: Castleview Partners previously reported a position in XBI as recently as Q4 2024.

Castleview Partners first reported a position in XBI in Q2 2021 and has held it in 14 quarters since. The position peaked at $367K in Q3 2024. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Castleview Partners held 1,602 shares of State Street SPDR S&P Biotech ETF worth $254K as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Castleview Partners position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.11% of Castleview Partners's portfolio in Q2 2026, its #184 holding.
Castleview Partners first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and has held it in 14 quarters since.
Castleview Partners's State Street SPDR S&P Biotech ETF position peaked at $367K in Q3 2024.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Castleview Partners's 13F filing for Q2 2026, filed 20 Jul 2026.